A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)


Journal Article

Full Text

Duke Authors

Cited Authors

  • Cloughesy, TF; Prados, MD; Wen, PY; Mikkelsen, T; Abrey, LE; Schiff, D; Yung, WK; Maoxia, Z; Dimery, I; Friedman, HS

Published Date

  • May 20, 2008

Published In

Volume / Issue

  • 26 / 15_suppl

Start / End Page

  • 2010b - 2010b

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2008.26.15_suppl.2010b


  • en